The biotech firm Archivel Farma, a CataloniaBio & HealthTech member, has created a subsidiary called Immuni Therapeutics to apply the RUTI® vaccine for Covid-19 (it is currently being developed for tuberculosis).
Archivel will grant an exclusive licence for RUTI® to the new company to show its clinical effectiveness and prepare the regulatory framework and the productive capacity.
The initial investment required is €2M. To achieve this, Immuni Therapeutics has opened up a round on the Capital Cell investment platform. With this financing, they could conduct three clinical trials in different countries and increase production capacity for the vaccine (currently 2 million units per year) to prepare the global roll-out starting in 2022.
Immuni Therapeutics is run by Luis Ruiz-Ávila, a well-known entrepreneur in the life sciences and healthcare ecosystem and one of the founders of CataloniaBio in 2006.
Photo: Pere-Joan Cardona, inventor of the RUTI® vaccine; Olga Rue, CEO of Archivel Farma, and Luis Ruiz-Ávila, CEO of Immuni Therapeutics.
Comments